Aldafermin
ngm biopharmaceuticals
[]
ngm bio announces presentation of data from phase 2 investigator-sponsored trial of aldafermin for the treatment of patients with diarrhea-predominant irritable bowel syndrome ( ibs-d ) and bile acid malabsorption ( bam ) at digestive disease week 2023 - ngm 
Finance enthusiast and renaissance man with a passion for learning, exploring, and creating. Enjoy posting news and musings. Proceed at your own caution.